SCHEMBL2269841

SCHEMBL2269841

O=C(Nc1cc(Oc2cccc(OC(F)(F)F)c2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF2BP2 Q9Y6M1 1/20 0.61
KCNK2 O95069 2/20 0.56
KCNK10 P57789 2/20 0.56
MAPK14 Q16539 1/20 0.53
PYGM P11217 2/20 0.52
HPSE Q9Y251 1/20 0.52
PYGL P06737 1/20 0.52
TDP1 Q9NUW8 3/20 0.50
GALK1 P51570 1/20 0.50
CASP6 P55212 1/20 0.50
MCL1 Q07820 1/20 0.50
PLEC Q15149 1/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
PKM P14618 1/20 0.50
GRIK1 P39086 1/20 0.50
KMT2A Q03164 1/20 0.50
SERPINE1 P05121 1/20 0.50
PGR P06401 1/20 0.49
DUSP3 P51452 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274009 0.93 IGF2BP2 (0.61) IGF2BP2KCNK2KCNK10MAPK14PYGM
SCHEMBL2271588 0.86 SERPINE1 (0.64) PYGMHPSEPYGLTDP1GALK1
SCHEMBL27848661 0.86 IGF2BP2 (0.49) IGF2BP2KCNK2KCNK10MAPK14PYGM
SCHEMBL2276941 0.86 IGF2BP2 (0.68) IGF2BP2KCNK2KCNK10TDP1MEN1
SCHEMBL2277696 0.86 MPO (0.59) KCNK2KCNK10MAPK14PYGMHPSE
SCHEMBL2269555 0.84 HPSE (0.55) PYGMHPSEPYGLTDP1GALK1
SCHEMBL2272040 0.84 PGR (0.69) KCNK2KCNK10PYGMHPSEPYGL
SCHEMBL2272432 0.84 PYGL (0.55) IGF2BP2KCNK2KCNK10MAPK14PYGM
SCHEMBL2275706 0.83 SERPINE1 (0.58) IGF2BP2KCNK2KCNK10MAPK14PYGM
SCHEMBL2272429 0.83 IGF2BP2 (0.71) IGF2BP2KCNK2KCNK10PYGMPYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 IGF2BP2 4173/4885KCNK2 3527/4885KCNK10 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.